Obesity, Gastrointestinal Health, Metabolic Health
Conditions
Interventions
1. Wheat-derived, Arabinoxylan-oligosaccharides (AXOS)
15g/day ingested with the meals (5 g in beverage, to be consumed three times a day)
2. Placebo: maltodextrin
15g/day ingested with the meals (
Sponsors
Maastricht University
Eligibility
Inclusion criteria
Inclusion criteria: Overweight to obese men and women (BMI ≥ 25 kg/m2 <35 kg/m2) - Aged 20-50 years - Caucasian - Normal fasting glucose (<6.1 mmol/L.) - Normal blood pressure (systolic blood pressure 100-140 mmHg, diastolic blood pressure 60-90 mmHg) - Weight stable in last 3 months (±2 kg) - A low defecation frequency, <3 times/week and no constipation or underlying pathology, as determined by gastro-intestinal questionnaires). - A low whole gut transit
Exclusion criteria
Exclusion criteria: 4.3 Exclusion criteria - Woman lactating, pregnant (where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test) or (post)-menopausal - Regular smokers - People with intensive fitness training, eg. athletes (≥3 per week ≥ 1 hour training) - Diabetes Mellitus (defined as FPG ≥ 7.0 mmol/l and or 2h PG ≥ 11.1 mmol/l) - Gastro-intestinal diseases or abdominal surgery, cardiovascular diseases, cancer, liver or kidney malfunctioning (determined based on ALAT and creatinine levels, respectively) disease with a life expectation shorter than 5 years - Following a hypocaloric diet - Gluten intolerance - Regular use of laxation products, or use of antibiotics, probiotics or prebiotics 3 months prior to the start of the study - More than 2 symptoms occurring over a period of 12 weeks in the preceding 12 months such as (1) Straining in >1/4 defecations; (2) Lumpy or hard stools in >1/4 defecations; (3) Sensation of incomplete evacuation in >1/4 defecations; (4) Sensation of anorectal obstruction/blockade in >1/4 defecations (5) Manual maneuvers to facilitate >1/4 defecations (e.g., digital evacuation, support of the pelvic floor); and/or (6) <3 defecations/week - Current use of medication interfering with study intervention or interfering with study endpoints/hypotheses - Not to be able to understand the study information - Blood donation 2 months prior to the study and during the study - Participation in other studies
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Whole gut transit time | — |
Secondary
| Measure | Time frame |
|---|---|
| Markers of gastrointestinal health | — |
Contacts
Public ContactMuller
Outcome results
None listed